Twomey J J, Laughter A H, Lazar S, Douglass C C
Cancer. 1976 Aug;38(2):740-7. doi: 10.1002/1097-0142(197608)38:2<740::aid-cncr2820380217>3.0.co;2-k.
Proliferative responses by blood and tumor lymphocytes to plant mitogens and allogeneic leukocyte antigens were tested concomitantly on 12 patients with Hodgkin's disease, 10 with chronic lymphocytic leukemia, and seven with non-Hodgkin's lymphomas. In 13 control studies, 3H-thymidine incorporation by blood and lymph node lymphocytes was brisk and, overall, comparable. With Hodgkin's disease, where extent of disease involvement and lymphocyte-depleted tumor histology were factors in the degree of responsiveness, incorporation was higher or at least comparable by tumor lymphocytes when compared with incorporation by autologous blood lymphocytes. Lymph node lymphocytes, especially with clinically stable disease, were more responsive than blood lymphocytes with chronic lymphocytic leukemia. Conversely, tumor lymphocytes were hyporesponsive compared with autologous blood lymphocytes with non-Hodgkin's lymphomas, where prognosis is usually less favorable than with chronic lymphocytic leukemia. Plasma from four out of 33 patients, although not lymphocytotoxic, inhibited lymphoproliferative responses.
同时对12例霍奇金病患者、10例慢性淋巴细胞白血病患者和7例非霍奇金淋巴瘤患者的血液和肿瘤淋巴细胞对植物有丝分裂原和同种异体白细胞抗原的增殖反应进行了检测。在13项对照研究中,血液和淋巴结淋巴细胞对3H-胸腺嘧啶核苷的掺入反应活跃,总体上具有可比性。在霍奇金病中,疾病累及范围和淋巴细胞消减型肿瘤组织学是反应程度的影响因素,与自体血液淋巴细胞的掺入相比,肿瘤淋巴细胞的掺入更高或至少相当。对于慢性淋巴细胞白血病,淋巴结淋巴细胞,尤其是在临床病情稳定的情况下,比血液淋巴细胞反应更强。相反,对于非霍奇金淋巴瘤,与自体血液淋巴细胞相比,肿瘤淋巴细胞反应低下,其预后通常比慢性淋巴细胞白血病更差。33例患者中有4例的血浆虽然没有淋巴细胞毒性,但能抑制淋巴细胞增殖反应。